



Tango Therapeutics Appoints Reid Huber, PhD, to Board of Directors

July 8, 2019

Leadership strengthened with appointment of Jannik N. Andersen, PhD, Head of Biology and Jeff Caravella, MBA, VP, Finance

CAMBRIDGE, Mass.--([BUSINESS WIRE](#))--[Tango Therapeutics](#), a biotechnology company committed to discovering and delivering the next generation of targeted cancer therapies, today announced the appointment of Reid Huber, PhD, to its Board of Directors.

Dr. Huber, a partner at Third Rock Ventures, has over 20 years of experience in biotech strategy and operations, ranging from early drug discovery to late-stage drug development. Prior to his work at Third Rock, Dr. Huber spent 16 years at Incyte, culminating in his role as Chief Scientific Officer.

"Reid has deep expertise in drug discovery and building innovative biotechnology companies. He was a founding member of Incyte's scientific team and ultimately served as CSO, bringing more than two dozen innovative molecules into clinical development, and he is now building exciting new companies as a partner at Third Rock Ventures," said Barbara Weber, MD, Tango's President and Chief Executive Officer. "His insights will be invaluable as we continue to advance our pipeline of next-generation targeted cancer therapeutics and build Tango into a fully integrated biotechnology company."

"Tango is unique in its laser-focused approach to discovering and developing cancer therapies that take aim at the genetic drivers of cancer," Dr. Huber said. "I'm delighted to join the board and contribute to bringing these genetically targeted therapies to patients in need."

Dr. Huber joined Third Rock Ventures in 2018 to focus on the formation, development and strategy of the firm's portfolio companies. He previously served in senior leadership roles at Incyte, as Executive Vice President and Chief Scientific Officer. Prior to that, Dr. Huber held positions of increasing responsibility at DuPont Pharmaceuticals and Bristol-Myers Squibb. Dr. Huber received his PhD in molecular genetics from the Washington University School of Medicine and held predoctoral and postdoctoral fellowships at the National Institutes of Health.

Tango also announced the appointments of two senior leaders in finance and biology: Jannik N. Andersen, PhD, as Vice President of Biology and Jeff Caravella, MBA, as Vice President of Finance.

Dr. Andersen's extensive expertise in basic and applied cancer research inform his work overseeing Tango's integration of functional genomics, drug discovery biology and translational and computational biology. Previously, Dr. Andersen held positions at large pharma companies (Novo Nordisk and Merck), biotech companies (Xtuit and Xios Pharmaceuticals) and major research hospitals (Dana-Farber Cancer Institute and MD Anderson Cancer Center). Dr. Andersen holds a Master of Science in chemical engineering from the Technical University of Denmark and a PhD in human biology from the Faculty of Medicine, University of Copenhagen. He completed his PhD thesis at Novo Nordisk and conducted postdoctoral studies at Cold Spring Harbor Laboratory in New York.

Mr. Caravella brings a wide range of strategic, business development and financial operations experience in the healthcare and life sciences industries. Prior to Tango, he served as Senior Director of Finance at Editas Medicine and as Head of Financial Operations for the global discovery and research models & services division of Charles River Laboratories. Mr. Caravella earned his MBA and Bachelor of Science from Syracuse University and also holds a Financial Planning and Analysis certification.

About Tango Therapeutics

Tango Therapeutics is a biotechnology company dedicated to discovering novel drug targets and delivering the next generation of targeted therapies to people with cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at driver genes in cancer. The company is focused on three core areas: counteracting tumor suppressor gene loss, reversing the ability of cancer cells to evade the immune system and identifying novel combinations that will be more effective than single agent therapy. Tango was launched in 2017 with a \$55 million Series A investment from Third Rock Ventures and announced a strategic collaboration with Gilead Sciences in November 2018 with a \$50 million upfront payment. For more information, please visit www.tangotx.com.



Stephanie Simon
Ten Bridge Communications
stephanie@tenbridgecommunications.com
617-581-9333